Vergoeding 2020-2024 voor ATC-subgroep L01EB : Egfr-tyrosinekinaseremmers
- Raming voor de totale Zvw-populatie
| 2020 | 2021 | 2022 | 2023* | 2024* | |
|---|---|---|---|---|---|
| L01EB01 Gefitinib | 1.046.312 | 313.227 | 140.640 | 70.416 | 40.732 |
| L01EB02 Erlotinib | 2.759.137 | 614.927 | 201.710 | 199.969 | 148.463 |
| L01EB03 Afatinib | 2.115.895 | 1.545.271 | 1.430.391 | 1.473.226 | 1.365.462 |
| L01EB04 Osimertinib | 41.514.429 | 56.456.627 | 61.475.939 | 67.720.185 | 68.998.770 |
| Totaal | 47.435.773 | 58.930.051 | 63.248.680 | 69.463.797 | 70.553.427 |